Ridgeback Capital Investments’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Ridgeback Capital Investments’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-52,509	Closed	-$332K	–	3
2022 Q4	$332K	Buy	+52,509	New	+$291K	0.4%	3
2022 Q1	–	Sell	-1,834,360	Closed	-$9.21M	–	3
2021 Q4	$9.21M	Buy	+1,834,360	New	+$11.1M	5.02%	3

Ridgeback Capital Investments's FSTX Position: Q1 2023 in Review

Ridgeback Capital Investments sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 52,509 shares — an estimated $332K sold.

Ridgeback Capital Investments first reported a position in FSTX in Q4 2021 and held it in 2 quarters. The position peaked at $9.21M in Q4 2021. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Ridgeback Capital Investments reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Ridgeback Capital Investments sold 52,509 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $332K.
Ridgeback Capital Investments first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
Ridgeback Capital Investments's F-star Therapeutics, Inc. Common Stock position peaked at $9.21M in Q4 2021.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Ridgeback Capital Investments's 13F filing for Q1 2023.